2015
Diagnostic application of KRAS mutation testing in uterine microglandular proliferations
Hong W, Abi-Raad R, Alomari AK, Hui P, Buza N. Diagnostic application of KRAS mutation testing in uterine microglandular proliferations. Human Pathology 2015, 46: 1000-1005. PMID: 25997988, DOI: 10.1016/j.humpath.2015.03.010.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBiopsyCell ProliferationCervix UteriDiagnosis, DifferentialDNA Mutational AnalysisEndometrial HyperplasiaEndometrial NeoplasmsFemaleHumansMiddle AgedMutationPredictive Value of TestsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsConceptsKRAS mutation analysisEndometrial adenocarcinomaMicroglandular hyperplasiaMicroglandular patternKRAS mutationsCareful morphological assessmentEndometrial mucinous carcinomaKRAS mutation testingCases of EMAMutation analysisFrequent KRAS mutationsElectronic medical recordsDifferential diagnostic toolHigh mitotic activityEndometrial biopsyImmunohistochemical workupUterine cervixMucinous carcinomaClinical historyDiagnostic challengeDiagnostic dilemmaGlandular proliferationMucinous lesionsMedical recordsEAC cases
2014
Egg Donor Pregnancy
Buza N, Hui P. Egg Donor Pregnancy. International Journal Of Gynecological Pathology 2014, 33: 507-510. PMID: 25083967, DOI: 10.1097/pgp.0b013e3182a1028b.Peer-Reviewed Original ResearchConceptsDonor pregnanciesMedical recordsClinical gestational ageFirst case reportPatients' medical recordsPositive nuclear stainingNormal staining patternVillous stromal cellsMaternal decidual tissuesDNA genotypingChorionic villous tissueGestational ageUnderwent dilationCase reportUterine contentsVillous tissueMorphologic featuresStromal cellsPregnancyStaining patternComplete hydatidiformPartial hydatidiformChorionic villiNuclear stainingMicroscopic evaluation
2013
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Modern Pathology 2013, 26: 1605-1612. PMID: 23765245, DOI: 10.1038/modpathol.2013.113.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaSerous carcinomaHER2 overexpressionEndometrial carcinomaMedical recordsImmunohistochemical scoreHER2 testingProtein expressionHER2 immunohistochemistrySignificant heterogeneityScoring systemMultiple tumor sectionsPure serous carcinomaHER2-positive casesHER2-positive tumorsScoring criteriaEndometrial carcinoma casesFDA criteriaPatients' medical recordsLarge academic centerHER2 FISH resultsHER2 protein overexpressionPromising therapeutic targetOverall concordance rateHER2 immunohistochemical scores